A little less than two years after tying up a multi-billion deal with Sanofi, DiCE Molecules scored another collaborative deal. The Bay Area company inked a multi-year collaborative agreement with Genentech to discover new small molecules.
Shire’s experimental treatment SHP609 to address cognitive impairment in pediatric patients diagnosed with the rare disease known as Hunter syndrome failed a key trial.
The FDA approved Spark Therapeutics’ treatment for a rare form of blindness, marking the first time the U.S. regulatory agency approved a gene therapy for an inherited disease.
The world’s largest chocolate makers are looking for ways to keep increasingly health-conscious consumers coming back for more.
U.S. health insurer Humana Inc. and two private equity firms agreed to buy home healthcare and long-term care operator Kindred Healthcare Inc. for about $810 million, the latest expansion by an American health insurer into patient care.
Dr. Reddy’s Laboratories will pay $5 million to resolve claims that the Indian company sold prescription drugs in the U.S. in packaging not tested for child safety.
The FDA approved Aerie Pharmaceuticals Inc.’s eyedrop Rhopressa as a treatment for glaucoma, two months ahead of the expected date.
Intouch Solutions, a leading marketing agency serving the pharmaceutical industry, announced the promotion of five employees in its Chicago office.
Novartis picked up a priority review voucher in a $130 million deal with California-based Ultragenyx Pharmaceutical Inc. The PRV is for rare pediatric diseases.